Morocco is taking a new step in the development of medical cannabis. Pharma 5 has officially introduced Cannabidiol Pharma 5, a locally developed and manufactured medicine based on purified cannabidiol (CBD), intended to treat certain forms of severe epilepsy that do not respond to conventional treatments. The launch marks a milestone for the country's pharmaceutical industry, bringing together Moroccan cannabis cultivation, scientific research and local pharmaceutical production.
Now available in Moroccan pharmacies since November 9, 2026, Cannabidiol Pharma 5 is an oral solution based on purified cannabidiol, a non-intoxicating compound derived from cannabis. It is intended for patients suffering from certain forms of drug-resistant epilepsy, also known as pharmacoresistant epilepsy, where seizures persist despite conventional anti-epileptic treatments.
The medicine contains CBD purified to more than 98%, meeting the standards of the European Pharmacopoeia. It is presented as an oral solution with two measuring pipettes and is positioned by Pharma 5 as a generic alternative to Epidyolex, the reference cannabidiol-based medicine used in the treatment of certain severe forms of epilepsy.
Importantly, this is a prescription medicine intended for specific medical indications, not a general cannabis or CBD wellness product.
Beyond the launch itself, one of the project's defining aspects is its local production model. Pharma 5 says it has developed an integrated chain covering every stage, from regulated cannabis cultivation in Morocco's Rif region to CBD extraction, purification and the manufacturing of the finished medicine.
The project represents five years of research and development, supported by an investment exceeding MAD 200 million. It also marks what the company describes as a national first in the production of a pharmaceutical active ingredient derived from cannabis entirely in Morocco.
The initiative was developed in coordination with national institutions, including the National Agency for the Regulation of Cannabis Activities (ANRAC) and the Moroccan Agency for Medicines and Health Products (AMMPS).
According to the company, the project also supports local agricultural communities, with around 40 hectares dedicated to regulated cannabis cultivation and approximately 70 farming families involved in the production chain.
The medicine is available in two formats. A box containing one 100 ml bottle is priced at 5,498 MAD, while a box containing three 100 ml bottles costs 13,401 MAD.
Pharma 5 says the treatment is priced more than 50% below the reference medicine in Europe, presenting it as a more affordable generic alternative. However, the medicine is not yet covered by health insurance, with its reimbursement file still under review by the relevant national health insurance authorities.
The launch of Cannabidiol Pharma 5 represents more than a new pharmaceutical product. It highlights Morocco's ambition to develop a regulated medical cannabis industry that goes beyond cultivation and includes research, pharmaceutical-grade processing and the production of finished medicines.
By controlling the production process locally, Pharma 5 is positioning Moroccan pharmaceutical expertise within a sector that continues to attract international attention. The development also creates new opportunities for agricultural communities and strengthens the country's capacity to transform locally sourced resources into higher-value medical products.
With Cannabidiol Pharma 5 now on the market, Morocco enters a new chapter in the development of therapeutic cannabis, connecting local agricultural production with pharmaceutical research and healthcare innovation.


